Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704294 | 1.00 | ACLY (0.41) | ACLYTSHRALDH1A1ACACBACACA | |
| SCHEMBL23217912 | 0.88 | ACLY (0.48) | ACLYTSHRALDH1A1ACACBACACA | |
| SCHEMBL23217911 | 0.88 | ACLY (0.48) | ACLYTSHRALDH1A1ACACBACACA | |
| SCHEMBL132109 | 0.76 | ACLY (0.43) | ACLYTSHRALDH1A1ACACBACACA | |
| SCHEMBL20533115 | 0.76 | ACLY (0.43) | ACLYTSHRALDH1A1ACACBACACA | |
| SCHEMBL132112 | 0.76 | ACLY (0.43) | ACLYTSHRALDH1A1ACACBACACA | |
| SCHEMBL10584864 | 0.76 | ACLY (0.48) | ACLYCYP2C19 | |
| SCHEMBL10584851 | 0.76 | ACLY (0.48) | ACLYCYP2C19 | |
| SCHEMBL28598936 | 0.75 | CYP4F2 (0.44) | TSHRALDH1A1CYP2C19 | |
| SCHEMBL2882121 | 0.74 | ALDH1A1 (0.48) | ACLYALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2023-11-23 | — | — | US | disclosed |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3359528-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE INC (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210253549-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2021-08-19 | — | — | US | disclosed |
| EP-3795566-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Mitobridge, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10906885-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3770146-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Mitobridge, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200157074-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2020-05-21 | — | — | US | disclosed |
| US-10479775-B1 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190337920-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-11-07 | — | — | US | disclosed |
| US-10399958-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190084958-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2017062468-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE, INC. (US) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157074-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | ACLY 479/4885TSHR 781/4885ALDH1A1 1587/4885 |
| US-20190337920-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | ACLY 479/4885TSHR 781/4885ALDH1A1 1587/4885 |
| US-10479775-B1 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | ACLY 479/4885TSHR 781/4885ALDH1A1 1587/4885 |
| US-20210253549-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | ACLY 479/4885TSHR 781/4885ALDH1A1 1587/4885 |
| US-20190084958-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARA, PPARD | ACLY 520/4885TSHR 850/4885ALDH1A1 2027/4885 |
| US-10399958-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARA, PPARD | ACLY 520/4885TSHR 850/4885ALDH1A1 2027/4885 |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | ACLY 479/4885TSHR 781/4885ALDH1A1 1587/4885 |
| US-10906885-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | ACLY 479/4885TSHR 781/4885ALDH1A1 1587/4885 |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | ACLY 479/4885TSHR 781/4885ALDH1A1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.